Forest Labs (FRX) Shares Tick Higher Following Headline of FDA Approval for Chronic Lung Disease Treatment

Article Stock Quotes (1) Comments (0)

Shares of Forest Labs (NYSE: FRX) have bounced more than a half percent following chatter of FDA approval for its drug to treat chronic lung disease. The stock is still down 1.2 percent to $34.47 at last check.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
• Best Buy (BBY) Hits New 52-Week High Into Q114 Report
• Shorts Buried in MLM Companies (HLF) (USNA) (NUS)

Create E-mail Alert Related Categories

Trader Talk

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?